Crohn's disease patients treated with injections of Remicade -- a biotech drug from Johnson & Johnson's Centocor unit -- alone or along with azathioprine pills were more likely to lose symptoms and discontinue the use of steroids compared with those who received only azathioprine, a company-funded study found. Patients will be evaluated for a year to determine whether the drug can help them avoid bowel surgery, a consultant to Centocor said.

Related Summaries